


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">31199578</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>06</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2040-1124</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Jun</Month>
                        <Day>14</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of diabetes investigation</Title>
                <ISOAbbreviation>J Diabetes Investig</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The protective effects of glucagon-like peptide-1 on cardiac remodeling by inhibiting oxidative stress through mammalian target of rapamycin complex 1 /p70 ribosomal protein S6 kinase pathway in diabetes mellitus.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1111/jdi.13098</ELocationID>
            <Abstract>
                <AbstractText Label="AIMS/INTRODUCTION" NlmCategory="UNASSIGNED">Although increased reactive oxygen species (ROS) generation is a major mechanism leading to cardiac remodeling in diabetes mellitus (DM), research into the effects of antioxidation on diabetic cardiac remodeling remains scarce and controversial. Glucagon-like peptide-1 (GLP-1) displays potential anti-oxidative effects besides lowering blood glucose. The objective of this research was to investigate the effects of GLP-1 on cardiac remodeling and the molecular mechanism involved in DM.</AbstractText>
                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Streptozotocin (STZ)-induced diabetic rats received exenatide treatment for 3 months. Cardiac function, cardiac weight index and myocardial interstitial fibrosis were measured. Cardiomyocytes were cultured in high glucose medium with GLP-1 treatment. The ROS production, apoptosis and the levels of mammalian target of rapamycin complex 1 (mTORC1)/p70 ribosomal protein S6 kinase (p70S6k) protein expression in cardiomyocytes were analyzed.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Experimental DM exhibited impaired cardiac diastolic function, increased brain natriuretic peptide expression, and increased interstitial collagen deposition in the myocardium, which were ameliorated by exenatide treatment. Exenatide reduced myocardial ROS production and apoptosis in DM. Also, high glucose-induced ROS generation and apoptosis in cardiomyocyte were inhibited by GLP-1, as well as the levels of mTORC1/p70S6k phosphorylation. Furthermore, GLP-1 treatment upregulated adenosine monophosphate activated protein kinase (AMPK) activity in high glucose-induced cardiomyocyte.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">GLP-1 protects the cardiomyocyte from oxidative stress and apoptosis in DM, which may contribute to the improvement of cardiac remodeling. The cardiac protection of GLP-1 may be dependent on inhibition of mTORC1/p70S6K, via an AMPK-mediated pathway. This article is protected by copyright. All rights reserved.</AbstractText>
                <CopyrightInformation>This article is protected by copyright. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Dongjuan</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Cardiology, Ningbo NO.2 Hospital, Ningbo, Zhejiang, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jiang</LastName>
                    <ForeName>Longfu</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Cardiology, Ningbo NO.2 Hospital, Ningbo, Zhejiang, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Feng</LastName>
                    <ForeName>Beili</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Cardiology, Ningbo NO.2 Hospital, Ningbo, Zhejiang, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>He</LastName>
                    <ForeName>Nana</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Stem Cell Laboratory, Ningbo NO.2 Hospital, Ningbo, Zhejiang, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Yue</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Cardiology, Ningbo NO.2 Hospital, Ningbo, Zhejiang, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ye</LastName>
                    <ForeName>Honghua</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Cardiology, Ningbo NO.2 Hospital, Ningbo, Zhejiang, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>06</Month>
                <Day>14</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Japan</Country>
            <MedlineTA>J Diabetes Investig</MedlineTA>
            <NlmUniqueID>101520702</NlmUniqueID>
            <ISSNLinking>2040-1116</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">cardiac remodeling</Keyword>
            <Keyword MajorTopicYN="N">diabetes mellitus</Keyword>
            <Keyword MajorTopicYN="N">glucagon-like peptide-1</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31199578</ArticleId>
            <ArticleId IdType="doi">10.1111/jdi.13098</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

